Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
TMS in pregnancy and the postpartum period appears to be a promising treatment option with no reports of adverse obstetric outcomes or congenital malformations.
There is evidence that depression itself can increase risk for hypertension and preeclampsia. Future studies will help to clarify the complex interaction between depression, SSRI treatment and pre-eclampsia.
At this point, the medical use of cannabis is legal in 37 states and the District of Columbia (D.C.). The recreational use of cannabis has been legalized in 21 states and D.C. The downstream effect [...]
Eating disorders are common among women during the childbearing years; however, information on eating disorders in pregnant and postpartum women is relatively sparse.
The largest study to date observes no increase in risk of autism or ADHD in children with prenatal exposure to benzodiazepines.
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?